Ryan Crowe
Tracked across 1 events · 7 articles · First seen May 18, 2026 · Last active Jul 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Ryan Crowe, Senior Vice President of Investor Relations at Regeneron Pharmaceuticals, made optimistic statements about the fianlimab + Libtayo trial that are now under investigation for potentially misleading investors.
May 18, 2026 · 7 articles
70
Ryan Crowe made allegedly misleading statementsRegeneron Securities Class...
ERGEN INTELLIGENCE
Track Ryan Crowe live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard